Navamedic Asa · OSL:NAVA
Navamedic Asa — Q1 2024 Earnings Presentation
25 slides from Navamedic Asa's earnings presentation, Apr 30, 2024
Slide 1: Q1 2024 Highlights and key figures
Q1 2024 Highlights and key figures 30 April 2024 Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Our edge explained
Our edge explained A reliable supplier of high-quality pharma products, within Prescription drugs (RX), Consumer Health, and Hospital products including Medical nutrition Presence and sales Strong local insight and across the Nordics understanding of patients’ needs Ambitious growth strategy With a
Slide 3: Key financial indicators | First quarter 2024
Key financial indicators | First quarter 2024 A quarter marked by a successful product launch, and steady operational progress Revenues in Q1 2024 were on same level as in previous year. Out of stock for Imdur in some markets REVENUE GROSS MARGIN Adjusted EBITDA Adjusted EBITDA in line with previous
Slide 4: The longer perspective
The longer perspective Growth on a scalable platform and through M&A +15% 500 200 400 150 Normal fluctuation in revenue growth between NOK million NOK million 300 quarters due to seasonality 100 and stock build-up/down effects 200 50 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021 2022 2023 Reve
Slide 5: High-quality portfolio with several hero products
High-quality portfolio with several hero products Prescription Drugs (RX) Consumer Health Hospital Sold through pharmacies Sold through pharmacies Tenders incl. medical nutrition* Q1 2024 Q1 2024 28.8 revenue in 58.4 revenue in 21% MNOK Q1 2024 15% MNOK -15% 33.8 revenue in MNOK YoY growth YoY chang
Slide 6: Prescription Drugs (RX)
Prescription Drugs (RX) Strong product growth across various therapeutic areas The RX segment comprises Navamedic’s prescription products 10% YOY GROWTH IN Strategy for growth MYSIMBA® WHOLESALER • Mysimba® lower sales • Focusing on individual VOLUME due to stock up in Q4. reimbursement in NO/FI Vol
Slide 7: Implementing commercialisation strategy for growth following the Sensidose acquisition
Implementing commercialisation strategy for growth following the Sensidose acquisition • Targeting patients with advanced Parkinson's disease • Marketing authorization for Flexilev in MyFID® • PD affects 1-2% of population already in place in 10 European countries above 60 years • Regulatory strateg
Slide 8: Hospital
Hospital Continued growth across the portfolio The Hospital segment comprises Navamedic’s antibiotics portfolio and medical nutrition products for the treatment of Inborn Errors of Metabolism (IEM) • Double digit growth for segment as a whole Strategy for growth • Steady growth for • Expand and secu
Slide 9: Consumer Health
Consumer Health Hero brands continue to deliver double digit growth The Consumer Health segment comprises Navamedic’s over-the-counter products, available to patients without a prescription Strategy for growth • Modifast has rebound after two slightly weaker • Launch, distribute, in- quarters licens
Slide 10: Successful rollout of Eroxon in Norway, Sweden to follow in May
Launching breakthrough treatment for erectile dysfunction ® Successful rollout of Eroxon in Norway, Sweden to follow in May • Navamedic markets and distributes Eroxon® in the Nordics. A clinically proven local treatment of erectile dysfunction, which can be bought without a doctor’s prescription • L
Slide 11: Eroxon launch: Massive attention, strong sales
Eroxon® launch Massive attention, strong sales 11
Slide 12: Delivering on our strategy for becoming a NOK 1 billion revenue company
Delivering on our strategy for becoming a NOK 1 billion revenue company GROWTH BASED ON A STRONG FOUNDATION 1 Untapping the potential within existing products, categories and territories. Strengthening the core with a disciplined approach to portfolio management, including adding attractive new prod
Slide 13: Financials
FINANCIALS @ Navamedic
Slide 14: Key consolidated profit and loss figures
Financials In Q1 2024, revenues were relatively flat compared to last year partly due to stock build-up of Mysimba at Key consolidated profit and loss figures wholesalers/pharmacies, and out-of- stock on some products (in NOK '1000) Q1 2024 Q1 2023 FY 2023 Gross Profit came in at 38.7% for Q1 Operat
Slide 15: Assets
Financials Assets (in NOK '1000) 31.03.24 31.03.23 31.12.2023 Goodwill 157 057 107 073 156 729 Deferred tax assets 930 835 930 Loan receivable is loan to Observe Other intangible assets 95 839 29 816 97 627 Medical (moved from non-current to Property, plant and equipment 3 599 671 3 692 current in t
Slide 16: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 31.03.24 31.03.23 31.12.2023 Total equity 226 157 225 389 222 391 Non-current interest-bearing borrowings 95 481 36 923 95 479 Non-current license liabilities 4 046 3 713 3 988 Non-current right of use liabilities 3 460 4 488 3 892 Equity ratio of 42%
Slide 17: Cash flow Group – total operations
Financials Cash flow Group – total operations The cash flow from Operating Activities (in NOK '1000) Q1 2024 Q1 2023 YTD 2023 is mainly the result of Net profit Net cash flow from operating activities - 5 563 3 099 2 179 coupled with changes in working Net cash flow from investing activities -185 -8
Slide 18: Summary & Outlook
SUMMARY & OUTLOOK @ Navamedic
Slide 19: Navamedic ASA summary and outlook
Navamedic ASA summary and outlook A quarter marked by a successful product launch, and steady operational progress TARGETS AND AMBITIONS • Navamedic delivered NOK 120.9 million in revenue in Q1 2024, relatively stable Targeting 20% annual growth compared to prior year • Q1 marked by stock build-up a
Slide 20: Q&A
Q&A 20 @ Navamedic
Slide 21: Want to know more?
Want to know more? Visit our website https://navamedic.com/ Follow us on LinkedIn #InvestInNavamedic Email infono@navamedic.com
Slide 22: Thank you for your attention!
Thank you for your attention! Navamedic’s Q2 2024 presentation will be held on 16 August 2024 22
Slide 23: Appendix
APPENDIX @ Navamedic
Slide 24: Basis for preparation and definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 25: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any